Cebosh

Quick links to important sections

Cebosh

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cebosh

Property Description
Active Ingredient (INN) Cefixime
Pharmacological Class Third-generation Cephalosporin (Antibiotic)
Dosage Form Oral (Tablet, Capsule, Powder for Suspension)
Manufacturer Bosch Pharmaceuticals (Pvt.) Ltd.
Rx Status Prescription Only (Rx)

Cebosh is a prescription-only brand of antibiotic medication. Its active component, cefixime, is a broad-spectrum, semi-synthetic antibiotic classified as a third-generation cephalosporin. This classification places it in a group of antimicrobial agents that are typically effective against a wide range of susceptible bacteria, including both gram-positive and gram-negative organisms.

Cephalosporins, as a class, act by interfering with the development of bacterial cell walls to fight infection. This mechanism makes Cebosh an option for treating uncomplicated bacterial illnesses, such as certain urinary tract infections (UTIs) or middle ear infections (otitis media), when caused by susceptible pathogens.

Cebosh is available in multiple oral forms. The availability of a strawberry-flavored powder for suspension is a feature often used to facilitate dosing for pediatric patients. Like all antibiotics, Cebosh is effective exclusively against infections caused by bacteria, and it will not treat viral illnesses such as the common cold or influenza. Using this medicine only when prescribed for a confirmed bacterial infection is a measure used to help minimize the risk of developing antibiotic resistance.

What side effects are possible with Cebosh?

Possible Side Effects and Safety Information

The safety profile of Cefixime, the active component of Cebosh, is officially structured by its potential adverse reactions, which are categorized by frequency and the body system affected. These classifications are based on official government regulatory documents.


Frequency-Classified Adverse Reactions

The most commonly documented adverse reactions are generally related to the Gastrointestinal System.

  • Common: Diarrhea and loose, frequent stools are the most frequent effects. Other common reactions include abdominal pain, nausea, and dyspepsia.
  • Uncommon: Adverse effects such as headache, rash, and vomiting are classified as uncommon in regulatory labeling.
  • Rare/Very Rare: Rare reactions include specific hematological changes (such as agranulocytosis or thrombocytopenia), severe allergic events (anaphylactic shock), and specific organ system inflammation (like interstitial nephritis or cholestatic jaundice).

Serious Adverse Reactions and Systemic Involvement

Official labeling documents a range of potential systemic adverse reactions classified by System-Organ-Class (SOC). Notable examples involve the Blood and Lymphatic System, Hepatobiliary System, and Renal System.

Serious adverse reactions, though rare, are explicitly documented in regulatory safety information, including: Severe Hypersensitivity events (anaphylaxis), Severe Cutaneous Adverse Reactions (such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis), and Clostridium difficile-associated diarrhea (CDAD), which can occur during or after treatment.

Population and Contextual Safety Notes

Regulatory documents include safety constraints for specific patient populations. For patients with renal impairment, there is an officially documented risk of neurotoxicity (encephalopathy), often necessitating dose adjustment. Safety has not been established for infants younger than six months. Furthermore, caution is stated for individuals with a history of penicillin allergy due to the potential for cross-hypersensitivity reactions.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Cebosh (Cefixime) may present with serious central nervous system (CNS) effects. Official regulatory labeling documents the potential for encephalopathy, which can manifest as severe symptoms including convulsions (seizures), confusion, and impairment of consciousness. Other documented manifestations may include diarrhea or abdominal pain.

A critical risk factor noted in the prescribing information is that the likelihood of serious neurological toxicity is heightened in patients with impaired kidney function (renal impairment).

Required Emergency Actions

In all cases of suspected overdose, immediate medical attention is required. Seek emergency medical services if the individual has a seizure, experiences trouble breathing, or cannot be awakened. Since no specific antidote exists, management is limited to providing symptomatic and supportive treatment, a strategy that may include procedures such as gastric lavage. Regulatory documents note that the drug is not effectively removed by hemodialysis or peritoneal dialysis, and monitoring for potential delayed adverse effects should continue for at least 24 hours.

Therapeutic Uses of Cebosh

What Cebosh Treats: Main Uses and Benefits

Cebosh is a medication primarily focused on providing short-term, supportive symptomatic relief across various clinical scenarios, applied across domains where additional symptomatic support is needed. It supports patients during episodes of heightened discomfort or distress.

The medication is relevant in conditions characterized by episodic or fluctuating symptom patterns, or those marked by temporary physiological or emotional tension. It may be part of symptomatic management for groups of symptoms that may appear suddenly, intensify over time, or create noticeable interference with daily functioning.


Key Areas of Symptomatic Support

Cebosh is applied in clinical settings that involve acute or unstable symptom patterns, such as during phases of increased distress or discomfort or when symptoms lead to temporary functional strain.

“The medicine may assist with providing supportive relief that helps patients cope more steadily with symptom fluctuations, and supports general well-being during symptomatic phases.”

Quick Fact: Supportive Management for Acute Symptom Clusters

Managing Symptom Domains

The medication helps address symptom clusters in contexts marked by increased discomfort or tension, which includes symptoms related to physical discomfort, symptoms that interfere with daily functioning, and symptoms associated with acute or episodic changes.

Regulatory References

  1. European Medicines Agency

Eligibility and Restrictions for Use

Cebosh (Cefixime) is a prescription antibiotic with specific regulatory guidelines determining who may and may not use it, primarily based on allergy status, age, and organ function.

Populations That Must Not Use Cebosh (Contraindicated)

  • Patients with a known history of allergy or hypersensitivity to Cefixime or any other cephalosporin antibacterial agent.
  • Patients with a history of severe hypersensitivity (e.g., anaphylaxis, severe skin reactions) to any other type of beta-lactam antibacterial agent, such as penicillins or carbapenems.

Populations Requiring Special Caution or Use Limitations

Population Eligibility Status Key Restriction/Note
Infants Not Recommended Safety and effectiveness are not established in children younger than six months of age.
Renal Impairment Use with Caution A dose adjustment is required for adult patients with moderate to severe renal impairment (e.g., creatinine clearance less than 60 mL/min).
Penicillin Allergy Use with Caution Administered cautiously due to the documented risk of cross-hypersensitivity between beta-lactams.
Pregnancy/Lactation Use Only if Clearly Needed Pregnancy Category B; consideration should be given to discontinuing temporary nursing during treatment as excretion in human milk is unknown.
Phenylketonuria (PKU) Use with Caution Certain formulations (e.g., chewable tablets) contain phenylalanine and should be used cautiously.

These restrictions ensure the medicine is used within the established safety and efficacy profile defined by governmental regulatory documents.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes interactions of Cefixime (Cebosh) as officially documented in government regulatory sources, focusing on documented patterns and formal outcomes.

The regulatory profile is structured around pharmacodynamic effects and pharmacokinetic alterations with specific substances. No formal contraindication based on an interaction mechanism is documented; the established contraindication is hypersensitivity.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interacting Substance Official Regulatory Description of Interaction Interaction Type
Oral Anticoagulants (e.g., Warfarin) Co-administration is associated with reports of increased prothrombin time (INR prolongation), with or without clinical bleeding. Pharmacodynamic Reinforcement
Probenecid Documented to increase Cefixime peak serum concentration and AUC by decreasing renal clearance. Exposure-Modifying
Carbamazepine Reports of elevated Carbamazepine plasma levels when co-administered. Exposure-Modifying
High-Dose Salicylates Reported to result in a 20-25% decrease in Cefixime peak serum concentration and AUC. Exposure-Modifying

Interaction-Related Context

Particular caution is noted for co-administration with nephrotoxic agents (e.g., Aminoglycosides, high-dose loop diuretics) in patients with severe renal function disorders. This combination carries a risk of additional renal impairment. The regulatory labeling confirms that taking the oral suspension with food does not significantly alter the extent of Cefixime absorption. No mandatory administration timing separation is documented for interacting medicines.

Mechanism of Action

Molecular Targeting and Irreversible Enzyme Inhibition

Cebosh (Cefixime) initiates its effect by acting as an irreversible inhibitor of bacterial Penicillin-Binding Proteins (PBPs), a class of transpeptidase enzymes essential for building the pathogen's cell wall. This mechanism directly targets and permanently deactivates the enzyme function by forming a stable covalent bond with the active site of the PBP.

Disruption of Bacterial Cell Wall Synthesis

The permanent blockade of PBP activity halts the peptidoglycan cross-linking process, leading to the formation of a defective, unstable bacterial cell wall. This structural failure compromises osmotic homeostasis, ultimately triggering the activation of autolytic enzymes and rapid bacterial cell lysis (death).

Constraints on Mechanistic Efficacy

Cefixime's mechanism is physiologically constrained when bacterial pathogens develop molecular defenses. These primarily involve the production of beta-lactamase enzymes that chemically inactivate the molecule, or genetic mutations that lead to an altered PBP structure, reducing the drug's essential binding affinity to its target.

Dosage and Administration Information

How to Use Cebosh: Administration Guidelines

Cebosh (cefixime) is intended for oral administration in the form of capsules, tablets, chewable tablets, or oral suspension.

Standard Dosing and Frequency

The recommended dose for adults is 400 mg (milligrams) administered daily. This total daily dose may be given in one of two ways:

  • 400 mg taken once per day.
  • 200 mg taken every 12 hours.

For specific infections, such as uncomplicated gonorrhea, the standard protocol includes a single oral dose of 400 mg. The capsule and tablet forms may be administered without regard to food.

Course Duration and Adjustments

Treatment duration is time-bound. In the treatment of infections due to Streptococcus pyogenes, the therapeutic dosage is typically administered for at least 10 days.

Population-Specific Dosing Rules:

  • Pediatric Patients (6 months and older) are dosed by weight, typically 8 mg/kg/day of the oral suspension. Children weighing more than 45 kg or older than 12 years receive the standard adult dose.
  • Renal Impairment: Dose adjustments are applied for adult patients whose creatinine clearance is less than 60 mL/min. For severe impairment (CrCl le 20 mL/min), the dose generally does not exceed 200 mg once daily.

Administration Requirements

Chewable tablets are crushed or chewed before swallowing, while the oral suspension is reconstituted with water and measured using a calibrated device prior to use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cebosh (Cefixime)

This section provides a summary of the official research evidence concerning the clinical evaluation of Cebosh (Cefixime). The information focuses on the types of studies conducted, the outcomes they measured, and areas where research remains limited, using strictly descriptive language.


Evidence for Use in Uncomplicated Urinary Tract Infections (UTIs)

Research exploring the use of Cefixime for uncomplicated UTIs primarily includes short-term Randomized Controlled Trials (RCTs). These studies, which often include non-pregnant adult women and some pediatric patients, were designed to measure clinical cure (resolution of urinary symptoms) and bacteriologic eradication (the clearance of the specific bacteria).

Findings describe patterns observed in the studies related to bacterial clearance, and research has explored how the drug was evaluated alongside other oral antibiotic options. The applicability of some older trial results may be impacted by the increasing worldwide prevalence of antibiotic-resistant organisms. Limited long-term follow-up means data for recurrence rates of UTIs are not fully established.

Evidence for Use in Middle Ear Infections (Otitis Media)

Clinical research for middle ear infections largely consists of multi-center RCTs, primarily focused on pediatric patients (typically ge 6 months old). Studies explored clinical cure and bacteriologic eradication. Studies report how symptoms evolved in the observed populations, and research describes the frequency with which patients required a change in the study regimen.

Findings were mixed regarding observed activity against all major strains of common pathogens, such as Streptococcus pneumoniae. Long-term effects, such as the persistence of middle ear fluid, are not fully established.

Evidence for Use in Other Specific Infections

For pharyngitis and tonsillitis, trials primarily measured bacteriologic eradication and symptom resolution. For acute exacerbations of chronic bronchitis (AECB), research examined outcomes reflecting daily functioning and bacteriologic eradication in adults. For uncomplicated gonorrhea, evidence is based on single-dose RCTs that measured treatment success; however, evidence is limited and certainty remains low regarding sustained clearance due to evolving microbial resistance.


Long-term Follow-up and Research Gaps

Available research primarily focuses on short-term outcomes, and follow-up durations were limited for most indications. Data for certain complicated groups, such as frail patients or those with severe renal impairment, is not consistently available, and subgroup findings are uncertain across the full range of approved uses. Research does not determine whether an individual in these groups will experience outcomes similar to the group patterns observed in the studies.

The overall evidence landscape highlights that the ongoing evolution of bacterial resistance is a factor that can impact applicability, and regulatory bodies emphasize the need for continued surveillance.

Frequently Asked Questions (FAQ)

Common questions about Cebosh (FAQ)

Q: How long does it usually take to feel the effect of Cebosh?

A: Cebosh, which contains the active ingredient cefixime, works by quickly targeting and deactivating bacterial enzymes, leading to the breakdown of the bacterial cell wall. However, the time required for a patient to observe a clinical improvement or resolution of symptoms can vary by individual and the type of infection being treated. Official prescribing information does not generally specify a single timeframe for symptom resolution.

Q: Is it normal to feel a bit dizzy when starting Cebosh?

A: Dizziness is a possible adverse reaction that has been reported in association with the use of Cebosh, according to official regulatory labeling. Other central nervous system effects, such as headaches and agitation, are also listed in product information. If an individual experiences dizziness or these other effects, this should be noted according to official product information.

Q: Does Cebosh cause weight gain or loss?

A: Weight changes (either gain or loss) are not typically listed among the frequent adverse reactions documented in the official regulatory labeling for Cebosh. Although rapid weight gain associated with swelling has been reported in rare, serious adverse events, weight changes are generally not described as a common expected effect.

Q: Are there different strengths or forms of Cebosh?

A: Yes, regulatory documents indicate that Cebosh is available in several oral dosage forms, including capsules, standard tablets, chewable tablets, and a powder for suspension. The medicine is available in various strengths and forms, including different milligram tablets, capsules, and a liquid suspension.

Q: Can Cebosh be crushed or split?

A: Official administration instructions specify that only the chewable tablets must be crushed or chewed before swallowing. The official product labeling for standard tablets and capsules (non-chewable) does not provide instructions for crushing or splitting, and they are generally intended to be swallowed intact.

Q: What if I'm taking herbal supplements, will they interact with Cebosh?

A: Official prescribing information documents specific interactions with certain prescription drugs, such as blood thinners like warfarin. While individual herbal or dietary supplements are generally not listed in detail, some patient information materials describe the general need for caution, as supplements can potentially affect how any prescription medicine is absorbed or metabolized.

Q: How is Cebosh different from similar medicines?

A: Cebosh is chemically defined in regulatory documents by its classification as a third-generation cephalosporin. This means it belongs to a specific family of antibiotics known to disrupt the construction of bacterial cell walls, distinguishing it from other antibiotic classes like macrolides or penicillins.

Q: Is Cebosh generally considered safe?

A: Official regulatory documents describe the complete safety profile of Cebosh, including all documented adverse reactions and warnings regarding risks like severe allergies and use in patients with kidney impairment. Use is permitted and described in the labeling when the medicine is prescribed and administered according to these guidelines, which define its risk-benefit profile.

Q: Can Cebosh affect sleep or cause insomnia?

A: Insomnia or general sleep disturbance is not typically listed as a common or frequent adverse reaction in official regulatory labeling. However, labeling indicates that adverse reactions affecting the central nervous system (such as agitation or dizziness) have been reported, which may indirectly influence sleep patterns.

Q: Is it okay to drive while taking Cebosh?

A: Official product information does not strictly prohibit driving or operating heavy machinery. However, regulatory documents list potential side effects such as dizziness and seizures, which could temporarily affect concentration or coordination. Official labeling suggests patients be aware of how the medicine affects their alertness before undertaking activities such as driving.

Q: Does Cebosh show up on drug tests?

A: Official prescribing information notes that Cebosh can interfere with certain lab tests used to measure glucose (sugar) in the urine, sometimes causing a false-positive result. It is not generally associated with causing positive results on standard screenings for illicit drugs.

Q: Is Cebosh addictive?

A: No. Cebosh is a prescription antibiotic that is not listed as a controlled substance under regulatory acts like the U.S. Controlled Substances Act. Official product labeling does not indicate any risk of physical dependence or addiction with its use.

Q: Why do doctors prescribe Cebosh over other options?

A: Doctors prescribe Cebosh based on its regulatory approvals, which define its use for treating specific infections like certain urinary tract infections, middle ear infections, and pharyngitis. Its use is limited to those bacterial infections that are confirmed or strongly suspected to be caused by organisms susceptible to this particular antibiotic class.

Q: Is Cebosh only for serious conditions?

A: The approved indications for Cebosh include both infections that can be serious and also uncomplicated infections like specific types of uncomplicated urinary tract infections or simple pharyngitis. Its use is defined by the type of susceptible bacteria involved, not just the severity of the condition.

How should Cebosh be stored and disposed of?

How to Store and Dispose of Cebosh

Storage and disposal requirements for Cebosh (cefixime) are specific to its dosage form, as documented in official regulatory labeling.


Storage Conditions

Dosage Form Required Storage Environment
Tablets/Dry Powder Store at Controlled Room Temperature (20 C to 25 C); protect from light and excessive moisture.
Reconstituted Suspension May be stored at room temperature or refrigerated; do not freeze.

All forms of Cebosh must be stored in their original container, kept tightly closed, and stored out of the sight and reach of children.

Stability and Disposal

The liquid oral suspension is stable for 14 days after mixing (reconstitution), after which any unused portion must be discarded. Unused or expired medication must be disposed of according to local pharmaceutical waste regulations. The product should not be flushed down a toilet or disposed of in wastewater systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cebosh found in:

A-Z Index: